PURPOSE: To investigate the efficacy and safety of selective radiotherapy after distant metastasis of @entity189 ( @entity189 ) treated with dose-dense @entity900 plus @entity1487 . MATERIALS AND METHODS: Eligible @entity1 were randomly assigned to a study group treated with dose-dense @entity900 plus @entity1487 following selective radiotherapy and a control group receiving traditional @entity900 plus @entity1487 following selective radiotherapy according to a 1:1 distribution using a digital random table method. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, relapse or progression rate in the radiation field and treatment @entity137 . RESULTS: Of 52 @entity1 in the study group, 20 cases underwent radiotherapy., while in the control group of 51 @entity1 , 16 underwent radiotherapy. The median PFS, median OS, survival rates in 1, 2 and 3 years in study and control group were 20.9 vs 12.7months, 28.3 vs 18.8months, 85.2%vs 65.9%, 62.2% vs 18.3%, and 36.6%vs 5.2% (p values of 0.00, 0.00, 0.04, 0.00 and 0.00, respectively). Subgroup analysis showed that the median OS and survival rates of 1, 2, 3 years for @entity1 undergoing radiotherapy in the study group better than that in control group( 43.2vs24.1 months, 94.1% vs 86.7%, 82.4% vs 43.3%, 64.7% vs 17.3%, (p=0.00, 0.57, 0.04 and 0.01, respectively). The complete response rate, objective response rate after chemotherapy and three months after radiotherapy, relapse or progression rate in radiation field in study group and in control group were 19.2% vs 3.9%, 86.5% vs 56.9%, 85% vs 50%, 95% vs 81.3% and 41.3% vs 66.7% (p =0.03, 0.00, 0.03,0.30, 0.01 respectively). The grade 3-4 acute adverse reactions in the study group were significantly higher than in the control group (53.8% vs 9.8%, p=0.00). CONCLUSIONS: The survival of @entity1 benefits from selective radiotherapy after distant metastasis of @entity189 treated with dose-dense @entity900 plus @entity1487 .

Selective Radiotherapy after Distant Metastasis of @entity189 Treated with Dose-Dense @entity900 plus XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma', 'NPC'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity1487 :: (MESH:D005472,Chemical) :: ['Fluorouracil']
